Fujifilm Diosynth Biotechnologies Continues Expansion of R&D Facilities Including Addition of Latest High Throughput Equipment

| Print |
Tuesday, 24 June 2014 18:15 (UTC + 2)

FujufilmDiosynth Logo

Billingham, Teesside, UK and Research Triangle Park, NC, USA, June 24, 2014 / B3C newswire / - Fujifilm Diosynth Biotechnologies has announced continued expansion of its process development capabilities with the investment of over US$5.6m in new laboratories and equipment at both its Billingham, UK and Research Triangle Park (RTP), NC, USA sites. This includes the first TAP ambr250™ automated bioreactor system for microbial fermentations to be commercially installed in a CDMO at the company’s Billingham, UK site. This investment further demonstrates the company’s commitment to use High Throughput technology and design of experiments to benefit its customers by rapid development of robust scalable processes for their biopharmaceutical production.

Also at the UK site, three laboratories have been upgraded and refurbished to accommodate the latest equipment, including new robotic chromatography platforms.

At the company’s RTP, NC site, four new process development labs have been added along with new equipment to allow greater flexibility for client project execution. This new equipment and expanded laboratory floor space for both process design and analytical support have significantly increased the development capacity for customer projects at the site.

Dr Mark Carver, Senior VP, R&D and Innovation, FUJIFILM Diosynth Biotechnologies says, “The purchase of this latest equipment, and upgrading of our laboratories across the business, keeps us at the forefront of technology for the development of robust and cost-effective manufacturing processes for biologics. Our ambr15 system has been working continuously since its installation in our mammalian cell culture laboratories 15 months ago, and we look forward to broadening our offering also to microbial fermentations by running multiple, single-use fermentations on this firstly-introduced ambr250. All of this new equipment, combined with the experimental design expertise of our highly trained scientists will allow us to produce ‘High Throughput Scale Down’ data for better process understanding, thereby enabling our customers to proceed more quickly to larger scale manufacture.”

He added “this investment forms part of our ongoing innovation activity and our commitment to lead the global Biologics CDMO industry through the continuous innovation of technologies, service delivery and quality for the benefit of our customers and their patients.”


About Fujifilm Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies UK Limited is an industry leading biologics Contract Development and Manufacturing Organization.  FUJIFILM Diosynth Biotechnologies has extensive experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial, mammalian, and insect systems.  The company offers a comprehensive list of services from microbial and mammalian cell line development, including its proprietary pAVEway™ system, to process development, analytical development, clinical and commercial manufacturing.  FUJIFILM Diosynth Biotechnologies is also located in Research Triangle Park, NC, USA as FUJIFILM Diosynth Biotechnologies U.S.A., Inc.  Both sites have been FDA-approved for the production of commercial biologic products.

About FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2014, the company had global revenues of $23.7 billion, at an exchange rate of 103 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship.


Contact

Bridget Hall, Communications Manager
FUJIFILM Diosynth Biotechnologies
Tel : +44 (0)1642 367320
Cell:  +44 (0)7796 938929
Email : This e-mail address is being protected from spambots. You need JavaScript enabled to view it
BIO : Booth #1127